Results 171 to 180 of about 3,349,066 (314)

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Could AI risk perception, AI learning anxiety and personal growth initiative influence university students' AI usage capability? An empirical investigation based on the control-value theory. [PDF]

Front Psychol
Jiang Y, Chen H.
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Factors Influencing Evidence-Based Practice Engagement Among Clinical Dietitians: A Mixed-Methods Study Using the COM-B Model. [PDF]

Healthcare (Basel)
Almudaihim A.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Development of the UK Rheumatology Occupational Therapy Capabilities Framework: a national consensus initiative. [PDF]

Rheumatol Adv Pract
Prior Y, Gregory WJ, Battista S, Bisset P, Derham S, Dockrell DM, Livesey C, Lyle S, Munakhya S, Murphy R, O'Callaghan G, O'Donnell K, Perkins J, Pidgeon C, Steer H, Tuson S, Walker E, Williams G.   +17 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Toward a family medicine capability framework for Canada: From competence to capability. [PDF]

Can Fam Physician
Aggarwal M, Scott G, Upshur REG, Katz A, Kulasegaram K.   +4 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Biofilm-forming capability of <i>Salmonella</i> isolates sourced from poultry production and farm environments in Great Britain. [PDF]

J Med Microbiol
Oastler C, La Ragione RM, Chambers MA, Gosling RJ, Martelli F, Wales AD, Davies RH.   +6 more
europepmc   +1 more source